For instance, the metabolically-dysregulated IR phenotype may be responsive to interventions aimed at improving mitochondrial flexibility, such as BCAA restriction, glycine supplementation, and AMPK activation, whereas the obesity-linked IR phenotype, they may benefit more from anti-inflammatory strategies, visceral fat reduction, and Glucagon-like peptide-1 (GLP-1) receptor agonists [20,42]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.